Display Settings:

Format

Send to:

Choose Destination
    J Neural Transm. 2006 Jan;113(1):59-73. Epub 2005 Oct 27.

    Serotonergic mechanisms in Parkinson's disease: opposing results from preclinical and clinical data.

    Source

    Department of Psychiatry and Neuropsychology, Institute of Brain and Behaviour, Maastricht University, Maastricht, The Netherlands. b.scholtissen@np.unimaas.nl

    Abstract

    Parkinson's disease (PD) is a neuropsychiatric disease affecting approximately 1-2% of the general population. The classical triad of symptoms, tremor, rigidity, and bradykinesia is mainly caused by degeneration of dopaminergic neurons from the substantia nigra. However, other neurotransmitter systems also show signs of degeneration, among which the serotonergic system. The exact role of serotonin in PD remains unclear. We present here a review about functional serotonergic interventions and serotonergic imaging studies in PD, and will go into the importance of combining preclinical and clinical research data in order to gain more insight into the role of serotonin in PD. More specifically, the present review is aimed at bridging the gap between data from animal models of PD and data from human research.

    PMID:
    16252066
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Springer

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk